Nano4
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m | <1m | <1m |
| % growth | 2234 % | 1469 % | 84 % | 17 % | (38 %) | - | - |
| EBITDA | <1m | (<1m) | (<1m) | <1m | - | - | - |
| % EBITDA margin | 3 % | (17 %) | (13 %) | 20 % | - | - | - |
| Profit | <1m | (<1m) | (<1m) | <1m | - | - | - |
| % profit margin | 3 % | (20 %) | (22 %) | 13 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€50.0k | Grant | ||
N/A | Grant | ||
€1.4m | Grant | ||
| Total Funding | AUD2.5m | ||
Related Content
Recent News about Nano4
EditNano4 Global is a forward-thinking startup founded in 2015, specializing in nanotechnology-based molecular diagnostics. The company operates in the healthcare and biotechnology market, focusing on providing fast, affordable, and highly accurate diagnostic tests. Nano4 Global's innovative platform is built on over 12 years of research and development conducted at the Universidade NOVA de Lisboa's Department of Life Sciences.
The company primarily serves healthcare institutions, clinics, and individual consumers. One of its notable services is the CoVID-19 molecular screening, which promises results within 24 hours. This service is particularly targeted at institutions and individuals in Portugal. Additionally, Nano4 Global is working on diagnostics for other diseases such as Chronic Myeloid Leukemia, tuberculosis, and Zika virus.
Nano4 Global's business model revolves around the commercialization of its proprietary nanotechnology platform. The company generates revenue by offering diagnostic tests to healthcare providers and individual clients. They also engage in partnerships with healthcare networks, such as CUF Hospitals and Clinics, to validate and expand the use of their diagnostics platform.
The company has been recognized for its innovative approach and has received several grants, including the SME Phase 1 and Phase 2 grants in 2017 and 2018, respectively. These grants have supported the company's research and development efforts, enabling them to bring their cutting-edge diagnostics to market.
The executive team at Nano4 Global boasts over 30 years of combined experience in life sciences, research, startups, and operations. This diverse expertise allows the company to effectively harness the potential of its technology and navigate the complexities of the healthcare market.
In summary, Nano4 Global is a pioneering startup in the field of nanotechnology-based molecular diagnostics, offering fast and affordable diagnostic solutions to healthcare institutions and individuals, primarily in Portugal.
Keywords: nanotechnology, molecular diagnostics, healthcare, biotechnology, CoVID-19, fast results, affordable tests, research, innovation, Portugal.